RU2712219C2 - Имидазопиразиноны в качестве ингибиторов pde1 - Google Patents

Имидазопиразиноны в качестве ингибиторов pde1 Download PDF

Info

Publication number
RU2712219C2
RU2712219C2 RU2017137514A RU2017137514A RU2712219C2 RU 2712219 C2 RU2712219 C2 RU 2712219C2 RU 2017137514 A RU2017137514 A RU 2017137514A RU 2017137514 A RU2017137514 A RU 2017137514A RU 2712219 C2 RU2712219 C2 RU 2712219C2
Authority
RU
Russia
Prior art keywords
pyrazin
methyl
imidazo
pyran
tetrahydro
Prior art date
Application number
RU2017137514A
Other languages
English (en)
Russian (ru)
Other versions
RU2017137514A3 (https=
RU2017137514A (ru
Inventor
Ян Кехлер
Ларс Кихн Расмуссен
Мортен Ланггард
Миккель Джессинг
Пауло Хорхе Виейра Витал
Карстен Джухл
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of RU2017137514A publication Critical patent/RU2017137514A/ru
Publication of RU2017137514A3 publication Critical patent/RU2017137514A3/ru
Application granted granted Critical
Publication of RU2712219C2 publication Critical patent/RU2712219C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017137514A 2015-04-30 2016-04-29 Имидазопиразиноны в качестве ингибиторов pde1 RU2712219C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA201500261 2015-04-30
DKPA201500261 2015-04-30
DKPA201500666 2015-10-29
DKPA201500666 2015-10-29
DKPA201600202 2016-04-04
DKPA201600202 2016-04-04
PCT/EP2016/059583 WO2016174188A1 (en) 2015-04-30 2016-04-29 Imidazopyrazinones as pde1 inhibitors

Publications (3)

Publication Number Publication Date
RU2017137514A RU2017137514A (ru) 2019-05-31
RU2017137514A3 RU2017137514A3 (https=) 2019-07-17
RU2712219C2 true RU2712219C2 (ru) 2020-01-27

Family

ID=55910242

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017137514A RU2712219C2 (ru) 2015-04-30 2016-04-29 Имидазопиразиноны в качестве ингибиторов pde1

Country Status (42)

Country Link
US (4) US20160318939A1 (https=)
EP (1) EP3288944B1 (https=)
JP (1) JP6663930B2 (https=)
KR (1) KR102605759B1 (https=)
CN (1) CN107531714B (https=)
AU (1) AU2016256573B2 (https=)
BR (1) BR112017023182B1 (https=)
CA (1) CA2983563A1 (https=)
CL (1) CL2017002719A1 (https=)
CO (1) CO2017010399A2 (https=)
CY (1) CY1121806T1 (https=)
DK (1) DK3288944T3 (https=)
DO (1) DOP2017000254A (https=)
EA (1) EA031946B1 (https=)
EC (1) ECSP17072228A (https=)
ES (1) ES2735422T3 (https=)
GE (2) GEAP201914615A (https=)
GT (1) GT201700223A (https=)
HK (1) HK1252098B (https=)
HR (1) HRP20191180T1 (https=)
HU (1) HUE044244T2 (https=)
IL (1) IL255316B (https=)
JO (1) JO3627B1 (https=)
LT (1) LT3288944T (https=)
MA (1) MA41977B1 (https=)
ME (1) ME03414B (https=)
MX (1) MX375737B (https=)
MY (1) MY182382A (https=)
PE (1) PE20180121A1 (https=)
PH (1) PH12017501990B1 (https=)
PL (1) PL3288944T3 (https=)
PT (1) PT3288944T (https=)
RS (1) RS59051B1 (https=)
RU (1) RU2712219C2 (https=)
SG (1) SG11201708822PA (https=)
SI (1) SI3288944T1 (https=)
SM (1) SMT201900393T1 (https=)
TN (1) TN2017000428A1 (https=)
TW (1) TWI695838B (https=)
UA (1) UA123050C2 (https=)
WO (1) WO2016174188A1 (https=)
ZA (1) ZA201706847B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
ES2967489T3 (es) 2016-10-18 2024-04-30 H Lundbeck As Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1
RU2019109039A (ru) * 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов, предназначенные для лечения психических и/или когнитивных расстройств
MX2019004859A (es) 2016-10-28 2019-06-20 H Lundbeck As Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
JP7111720B2 (ja) 2016-12-28 2022-08-02 ダート・ニューロサイエンス・エルエルシー Pde2阻害剤としての置換ピラゾロピリミジノン化合物
CA3120971A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
WO2019121840A1 (en) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
AU2019275453B2 (en) 2018-05-25 2023-12-21 Intra-Cellular Therapies, Inc. Organic compounds
WO2020210614A1 (en) 2019-04-12 2020-10-15 Intra-Cellular Therapies, Inc. Organic compounds
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006138624A (ru) * 2004-04-02 2008-05-10 Оси Фармасьютикалз, Инк. (Us) 6, 6-бициклические кольцевые замещенные гетеробициклические ингибиторы протеинкиназ
US20080194592A1 (en) * 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
US20110281832A1 (en) * 2008-12-06 2011-11-17 Peng Li Organic compounds
WO2013053690A1 (en) * 2011-10-10 2013-04-18 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
CA2524900C (en) 2003-05-09 2012-03-20 Bayer Healthcare Ag 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
WO2006068978A2 (en) * 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
EP2227472A1 (en) 2007-11-30 2010-09-15 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
JP5453431B2 (ja) * 2008-09-08 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラゾロピリミジン及びcns障害の治療のためのそれらの使用
WO2010065147A1 (en) * 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
PT3042917T (pt) 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
RU2603140C2 (ru) 2010-09-20 2016-11-20 Айронвуд Фармасьютикалз, Инк. Соединения имидазотриазинона
US20130196986A1 (en) 2010-09-21 2013-08-01 Marc Labroli Triazolopyrazinones as p2x7 receptor antagonists
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
BR112014018199A8 (pt) 2012-01-26 2021-03-02 H Lundbeck As inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
JP2013166727A (ja) * 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
MX357320B (es) 2012-06-18 2018-07-04 Dart Neuroscience Cayman Ltd Compuestos de la azolopirimidina-5-(6h)-ona de piridina sustituida.
CA2906640C (en) 2013-03-15 2021-07-20 Intra-Cellular Therapies, Inc. Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
CN106029639B (zh) 2014-02-19 2019-01-08 H.隆德贝克有限公司 治疗阿尔茨海默病的bace1抑制剂的2-氨基-3,5,5-三氟-3,4,5,6-四氢吡啶
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
WO2016042775A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
JP2018508555A (ja) 2015-03-16 2018-03-29 大日本住友製薬株式会社 二環性イミダゾロ誘導体
US20160311831A1 (en) 2015-04-22 2016-10-27 H. Lundbeck A/S Imidazotriazinones as PDE1 Inhibitors
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
AU2016305275A1 (en) 2015-08-12 2018-02-08 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
ES2967489T3 (es) 2016-10-18 2024-04-30 H Lundbeck As Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1
RU2019109039A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов, предназначенные для лечения психических и/или когнитивных расстройств
MX2019004859A (es) 2016-10-28 2019-06-20 H Lundbeck As Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006138624A (ru) * 2004-04-02 2008-05-10 Оси Фармасьютикалз, Инк. (Us) 6, 6-бициклические кольцевые замещенные гетеробициклические ингибиторы протеинкиназ
US20080194592A1 (en) * 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
US20110281832A1 (en) * 2008-12-06 2011-11-17 Peng Li Organic compounds
WO2013053690A1 (en) * 2011-10-10 2013-04-18 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone

Also Published As

Publication number Publication date
US11472810B2 (en) 2022-10-18
US10858362B2 (en) 2020-12-08
KR20170140216A (ko) 2017-12-20
BR112017023182A2 (https=) 2018-10-02
SI3288944T1 (sl) 2019-08-30
HK1252098A1 (en) 2019-05-17
JP2018514552A (ja) 2018-06-07
SG11201708822PA (en) 2017-11-29
KR102605759B1 (ko) 2023-11-23
US20160318939A1 (en) 2016-11-03
GT201700223A (es) 2018-12-19
ME03414B (me) 2020-01-20
CA2983563A1 (en) 2016-11-03
ES2735422T3 (es) 2019-12-18
EA031946B1 (ru) 2019-03-29
US20170291903A1 (en) 2017-10-12
TN2017000428A1 (en) 2019-04-12
WO2016174188A1 (en) 2016-11-03
JO3627B1 (ar) 2020-08-27
RS59051B1 (sr) 2019-08-30
MA41977A (fr) 2018-07-23
UA123050C2 (uk) 2021-02-10
MA41977B1 (fr) 2019-08-30
IL255316A0 (en) 2017-12-31
AU2016256573A1 (en) 2017-12-14
BR112017023182B1 (pt) 2023-10-31
MX2017013785A (es) 2018-03-27
DOP2017000254A (es) 2018-01-15
PT3288944T (pt) 2019-07-19
US10011606B2 (en) 2018-07-03
US20210238182A1 (en) 2021-08-05
LT3288944T (lt) 2019-07-25
ECSP17072228A (es) 2018-02-28
MX375737B (es) 2025-03-06
PE20180121A1 (es) 2018-01-18
CL2017002719A1 (es) 2018-04-20
CY1121806T1 (el) 2020-07-31
US20190062335A1 (en) 2019-02-28
EP3288944A1 (en) 2018-03-07
HUE044244T2 (hu) 2019-10-28
AU2016256573B2 (en) 2019-11-21
EA201792157A1 (ru) 2018-03-30
TW201700477A (zh) 2017-01-01
RU2017137514A3 (https=) 2019-07-17
PH12017501990A1 (en) 2018-03-26
TWI695838B (zh) 2020-06-11
HK1252098B (en) 2020-02-07
SMT201900393T1 (it) 2019-09-09
GEP20207058B (en) 2020-01-27
ZA201706847B (en) 2019-01-30
CN107531714A (zh) 2018-01-02
JP6663930B2 (ja) 2020-03-13
RU2017137514A (ru) 2019-05-31
DK3288944T3 (da) 2019-07-22
PH12017501990B1 (en) 2021-01-13
HRP20191180T1 (hr) 2019-10-04
PL3288944T3 (pl) 2019-11-29
MY182382A (en) 2021-01-22
CO2017010399A2 (es) 2018-01-05
GEAP201914615A (en) 2019-09-25
IL255316B (en) 2021-10-31
CN107531714B (zh) 2019-07-19
EP3288944B1 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
RU2712219C2 (ru) Имидазопиразиноны в качестве ингибиторов pde1
US10912773B2 (en) Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors
EP3532064B1 (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
EA035197B1 (ru) 1,5-ДИГИДРО-4H-ПИРАЗОЛО[3,4-d]ПИРИМИДИН-4-ОНЫ И 1,5-ДИГИДРО-4H-ПИРАЗОЛО[4,3-c]ПИРИДИН-4-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1
OA18771A (en) Imidazopyrazinones as PDE1 Inhibitors
HK40005946A (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
HK40005946B (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders